Facebook
Twitter
LinkedIn
Forward
Establishing Frameworks for Precision Medicine in NTRK Fusion-Positive Advanced Solid Tumors
November 11, 2024
Self Regional Healthcare Cancer Center
Despite significant advancements over the past decade, significant unmet needs persist for patients with NTRK-positive locally advanced or metastatic solid tumors. In addition, there is ongoing debate about the importance of testing for genomic alterations in rare cancers, or those that rarely occur in common cancers. However, evolving molecular testing procedures and emerging therapeutic options targeting NTRK fusions offer new pathways for the detection and treatment of these cancers. Using expert-developed, peer-reviewed content, leaders at cancer centers will facilitate a 1-hour learning and action planning program with their clinical team to review and enhance their diagnostic-therapeutic paradigms to support improved testing for rare genomic alterations and optimize treatment selection practices.
Educational Partner: Academy for Continued Healthcare Learning (ACHL)
Commercial Support: Support for this activity has been provided through an educational grant from Bristol Meyers Squibb.
Commercial Support: Support for this activity has been provided through an educational grant from Bristol Meyers Squibb.
Target Audience
This activity is created for medical oncologists, pathologists, nurse practitioners, physician assistants and APNs who care for patients with NTRK fusion-positive cancers.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Review optimal testing strategies to detect NTRK fusions in patients with cancer
- Assess efficacy and safety data of current and emerging TRK inhibitors for patients with NTRK fusion-positive advanced solid tumors
- Establish operational frameworks to improve precision medicine practices in patients with NTRK fusion-positive cancers
You may also be interested in
Webinar
Greenwood, SC
United States
WANT TO KNOW MORE?
Visit the Academy for Continued Healthcare Learning (ACHL) website!
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at https://www.achlcme.org/.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
FACULTY
Alexander Drilon, MD
Chief, Early Drug Development
Assistant Attending, Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Chief, Early Drug Development
Assistant Attending, Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Jeremy Segal, MD, PhD
Professor, Pathology
University of Chicago
Director, Molecular and Cytogenic Pathology
University of Chicago Medicine
Chicago, IL
Professor, Pathology
University of Chicago
Director, Molecular and Cytogenic Pathology
University of Chicago Medicine
Chicago, IL
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
REGISTRATION: Registration is not open to the public.
For questions or more information, visit the ACHL website or click the button below!
For questions or more information, visit the ACHL website or click the button below!
Please login or create an account to proceed.